Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent
| Autor: | Manfred Windisch, H. Moessler, M. Panisset, Serge Gauthier |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Heterozygote medicine.medical_specialty Placebo-controlled study Placebo Placebos Central nervous system disease Disability Evaluation chemistry.chemical_compound Apolipoproteins E Cognition Double-Blind Method Gene Frequency Alzheimer Disease Internal medicine medicine Humans Dementia Amino Acids Psychiatry Adverse effect Alleles Biological Psychiatry Aged Aged 80 and over Psychiatric Status Rating Scales Depression Middle Aged medicine.disease Psychiatry and Mental health Neuroprotective Agents Phenotype Treatment Outcome Neurology chemistry Cerebrolysin Female Neurology (clinical) Age of onset Alzheimer's disease Psychology |
| Zdroj: | Journal of Neural Transmission. 109:1089-1104 |
| ISSN: | 1435-1463 0300-9564 |
| DOI: | 10.1007/s007020200092 |
| Popis: | Cerebrolysin (Cere) is a compound with neurotrophic activity. It has been shown to be effective in the treatment of Alzheimer's disease (AD) in earlier trials. In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks. Effects on cognition and global function were evaluated with the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinicians Interview-based Impression of Change with Caregiver Input scale (CIBIC+) 4, 12, 24 weeks after the beginning of the injections. 192 patients were enrolled, 95 were randomized to placebo, and 97 to Cere. At baseline, there was a significant difference between groups for age, age of onset of dementia, and the number of patients with hallucinations. At week 12 there was a significant difference on the CIBIC+ (p = 0.033) in favor of Cere. The number of CIBIC+ responders (scoreor = 4), was significantly higher (p = 0.007), with 68 (76%) in the Cere group and 51 (57%) in the placebo group. Trends were noted in the Disability Assessment in Dementia scale and the Cornell Depression Scale. Adverse events were recorded in 73% of placebo and 64% of Cere patients. Most common adverse events were headaches, dizziness, weight loss and anxiety.Cere treatment was well tolerated and resulted in significant improvements in the global score two months after the end of active treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink